Microburst Insulin Infusion (MII) Treatment and Upon-Completion Evaluation

Pulsed intravenous insulin therapy (PIVIT) has brought about ambiguous results in studies that examine metabolic control. Microburst insulin infusion is a treatment procedure on the use of a uniquely-designed pump that mimics the amplitude of normal and natural pancreatic function with more efficacy and closeness than other pulsatile insulin therapeutic approaches in use for many years without much success. Mitokon Health Center using Trina Treatment is a company with premium diabetes treatment centers in Chesterfield, Missouri with specialist doctors that treat diabetes using Microburst insulin infusion approach; a replacement for the less effective conventional diabetes treating approach.

A Basic Rundown of the Initial Consultation in Our Company

Mitokon Health Center’s Trina treatment system is for every patient from the day of their initial consultation to the completion of treatment in our diabetes treatment centers in Missouri. That’s from step 1 through step 2 to step 3 upon completion, evaluation, and discharge.

  • Capturing vital signs or clues of diabetes in a seemingly sometimes healthy person is the first thing to do.
  • Identifying glucose levels by diagnosing the person to determine whether their glucose level is low or high will follow next. If it is high, then an appropriate medical response will be made.
  • Reviewing medications after diagnoses to determine the right personalized treatment required for either Type 1 or Type 2 diabetes. At Mitokon Health Center, our expert doctors provide microburst insulin infusions, the most appropriate treatment for diabetes patient right now.
  • Assessing the overall condition of the patient and what their treatment is going to be like in response to the microburst insulin infusions our doctors will offer them.
  • At this point, the doctors can review the personalized treatment plan for the patient.
  • Lastly, the doctor can set an appointment to begin treatment and follow the progress of patients until the evaluation upon completion and discharge.

The 3rd step; evaluation and discharge upon completion takes place in the most professional way possible owing to the risk involved in not rendering an effective treatment. In the 3rd and final step of the treatment of the diabetic patient after our Microburst Insulin Infusion (MII) Treatment can like many others give testimonials of the relief our treatment has rendered them.

Right after the Completion of the Treatment

Because the body may as well be producing its own insulin, that causes some patients to constantly feel hunger for carbohydrates. For those who may feel such hunger, carbohydrates would be good for them to take but after that, checking their blood sugar would be medically quite advisable.

The majority of patients report a great night’s sleep as Microburst Insulin Infusion (MII) Treatment returns to the circadian rhythm of blood pressures.

After Undergoing Treatment

Our patients will gladly report feeling progressively better after each of these diabetes treatment sessions. This is when they will for the first time in years start to feel their feet again after many years. Also, their eyesight will begin to function normally again, and colors will seem clearer, provided the patient had suffered from such a health problem previously. They will experience skin color improvement as a result of proper metabolism. Besides, wounds will begin to heal and old scars healing as if by themselves. With our Trina treatment, our patients report that there is a significant feeling of sound health receiving 3-5 treatments.

From Conventional To Advanced Diabetes Treatment

Microburst insulin therapy is a new advancement in the treatment of diabetes, to retard the many complications of insulin and the ability to closely replicate natural and normal pancreatic function

In summation, conventional insulin therapy has not achieved anything beyond partial success in treating diabetes and preventing chronic complications. Unsatisfying insulin efficacy in the treatment of diabetes may be because of the quality of exogenous insulin and not because of the possibility of physiologic “inadequacy” of its method of administration.